2 Minutes with Joey - PFE Stock News

Avsnitt

• 
  PFE Today - Aug 13: CEO Buys Stock 13.08.2026 1min

  Hey there! It’s Joey, your friendly stock enthusiast, here to break down what happened with Pfizer today. So, PFE had a pretty solid day, up about 1.5%. Not too shabby, right? Now, let’s get into it. The big news was that Pfizer’s CEO decided to drop a cool million on some company stock. That’s a bold move, and it definitely got some folks talking. When the head honcho puts their money where their mouth is, it usually sends a message. Plus, there’s been buzz around their Lyme disease vaccine showing some impressive numbers—70% efficacy, which is a big deal in the vaccine world. But not everything was sunshine and rainbows. Some articles pointed out that Pfizer’s stock has been lagging compared to its competitors. A few analysts were like, “What’s going on here?” They noted that while the CEO’s buy is a good sign, the stock has been underperforming, and there’s some chatter about whether it’s time to sell. Honestly, the market can be a bit of a rollercoaster, and nobody really knows why it’s moving the way it is sometimes.Oh, and here’s a quick heads up: there’s some talk about how Pfizer might be getting into a subscription model for their products, similar to what Novo Nordisk is doing with Wegovy. That could be interesting to watch.So, to wrap this up: Pfizer had a decent day, thanks in part to the CEO’s big buy and some promising news on the vaccine front. But there’s still some skepticism in the air about its overall performance. Just remember, this is all for fun and information—no financial advice here. Catch you next time!
• 
  PFE Today - Aug 12: Lagging Stock Performance 12.08.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor, breaking down the day for ya. Today, we’re talking about Pfizer, or PFE, and it had a rough go, closing the day in the red, down about 1.3%. Ouch.So, what went down? Well, PFE got smoked today. There’s been a lot of chatter about their stock lagging behind the competition, and it’s pretty clear that investors weren’t feeling it. People hit the sell button fast, and the stock didn’t really bounce back. It’s like everyone’s just waiting for something good to happen, but today was not that day.Now, why did this happen? One big reason floating around is that Pfizer just raised its earnings guidance for 2026, but hold up — it’s heavily relying on a drug that’s about to run out of its patent. That’s like putting all your eggs in a basket that’s got a hole in it. And there’s also this talk about them shelling out a whopping $49 billion in payouts, which is making folks a bit nervous. Add to that the fact that when you stack Pfizer against competitors, it’s been underperforming. Just not a great look.Oh, and one more thing on the horizon — Erste Group Bank just bumped up their earnings estimates for Pfizer. So, there’s a glimmer of hope, but it’s kinda overshadowed by all the other stuff going on.So yeah, today was a bit of a bummer for PFE. Just remember, I’m here to keep you in the loop, not to give you stock tips. Catch you later!
• 
  PFE Today - Aug 11: Earnings Decline Sparks Concerns 11.08.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor. Today, we’re talking about Pfizer, and it was a red day for them. The stock dipped about half a percent. Ouch!So here’s the scoop. Pfizer’s been on a bit of a rollercoaster lately. Today’s drop follows a pretty rough earnings report where they revealed their earnings have tanked by 58% this year. Yeah, that one stung. Investors are getting a little jittery, wondering if a dividend cut might be on the way. Nobody likes to hear that, especially if you’re counting on those payouts.Now, why did this happen? Well, analysts are buzzing after the earnings call, asking tough questions about Pfizer’s future. It’s clear folks are concerned about how the company’s navigating post-COVID realities. While some are optimistic about their pipeline, others are skeptical, especially with the looming prospect of a dividend cut. You know, when the money gets tight, companies often look to trim those dividends, and that’s got investors hitting the sell button pretty fast.To add to the mix, there’s been some chatter about how Pfizer’s stock has been rallying for seven straight sessions before today’s dip. It’s like a classic case of “what goes up must come down.” In the backdrop, while Wall Street seems to be pretty bullish overall, retail investors are a bit more cautious. They might be looking at Pfizer and thinking, “Is this really the smart play?”One thing worth keeping an eye on is the ongoing discussion about whether Pfizer or Merck is the better dividend stock. Analysts are really weighing in on that, and it could shift sentiment as we move forward. So, to wrap it up, Pfizer’s facing some serious scrutiny after those earnings, and people are feeling a little uneasy about what’s next. It’s a wild ride in the stock market, and sometimes it’s hard to predict which way the wind’s blowing. Just remember, this is all for fun and info, not financial advice. Catch you later!
• 
  PFE Today - Aug 10: Strong Q2 Results Boost Stock 10.08.2026 1min

  Hey there! It's Joey here, your friendly neighborhood investor, breaking down the day’s action. Today we're chatting about Pfizer, and it was a green day for them! The stock was up a little over a third of a percent. Not huge, but hey, green is good, right?So, what happened? Pfizer's been riding a bit of a wave after dropping their Q2 results. They jumped almost 7% right after those numbers came out. Pretty solid response! But today, it looks like the excitement simmered down a bit, and they just kinda floated along. You know how it is—sometimes the hype just cools off.Now, why did the stock move like this? Well, folks are feeling a bit optimistic after Pfizer revealed plans to ramp up cost-cutting. They’re looking to tighten the belt, which is usually a good sign for investors. Plus, the company’s also been thrown into the spotlight for being one of the top picks in the AI healthcare space. So, it’s like they’ve got a couple of things going for them right now, which is nice to see.Oh, and here's a quick note on what’s happening next: Pfizer shares are offering a yield of 6.4%. That’s pretty appealing, especially when you compare it to what Wall Street was expecting. So, that might keep some eyes on the stock in the coming days.So, to wrap it up, Pfizer had a decent day, buoyed by some solid earnings and a cost-cutting plan that got people talking. Just remember, I’m just here to share what’s going on, not to give you any financial advice. Keep it chill, and I’ll catch you later!
• 
  PFE Today - Aug 09: Pfizer's Earnings Beat Sparks Interest 09.08.2026 1min

  Hey, what’s up? It’s Joey here, your friendly investor buddy, breaking down the day for you. Today we’re talking about Pfizer, and guess what? It had a pretty solid green day, up about 2%. So, here’s the scoop. Pfizer's stock caught some good vibes today, moving higher after they reported their earnings. They actually beat the estimates, which is always a nice surprise, right? And they’re eyeing some serious cost cuts, targeting around $2.5 billion. That’s a big chunk of change! People seemed to like the sound of that, so they were hitting the buy button. Now, let’s talk about why this is happening. Pfizer’s been through a lot lately. They’ve had their triumphs, especially with the COVID vaccine, but they’re also grappling with some challenges. The buzz is that they’re trying to pivot and find new ways to stay relevant in the healthcare game. There’s been chatter about their Lyme disease vaccine showing some real promise too, with reports of 70% efficacy. That’s got to feel good for them! But yeah, it’s a mixed bag for Pfizer, and they’re navigating some rough waters post-COVID.Oh, and one more thing to keep an eye on: they’re also being mentioned as one of those AI healthcare picks. Seems like they’re trying to tap into that tech side to boost their game. That could be interesting to watch as it develops.So, all in all, Pfizer had a decent day, with some positive earnings news and a little hope for the future. Just remember, I’m here to share info and keep it casual, not to give you financial advice. Catch you later!
• 
  PFE Today - Aug 08: Pfizer's Lyme Vaccine Shines 08.08.2026 1min

  Hey there! It’s Joey, your friendly stock guy, and I’ve been in the investing game for a while now. Today, we’re talking about Pfizer, and it was a green day – nice to see that 2.06% bump!So, what went down? Pfizer’s stock got a little boost today, moving up a bit, and you know what? It actually outperformed some of its competitors. That's always a nice surprise. Traders were definitely feeling a bit more optimistic about it today.Now, the big news fueling that little jump? It’s all about Pfizer’s Lyme disease vaccine showing some solid results with a 70% efficacy rate. That’s a huge deal, especially since Lyme disease can be a real pain for so many people. This news seems to have brightened the mood around Pfizer, especially after they’ve been grappling with a lot of challenges post-COVID. Yeah, that one stung a bit for them, but it looks like they’re trying to bounce back with new products.On the flip side, there were some whispers about other companies in the space, like BioNTech and Novo Nordisk, so there’s definitely some competition heating up. But hey, Pfizer’s got its sights set on some new weight-loss treatments too, which could be interesting down the road.One thing worth keeping in mind is that Pfizer’s stock has been pretty volatile lately, so it’s good to stay informed. They’ve got some big plans ahead, and it’ll be interesting to see how they play out.Alright, that’s a wrap for today! Just remember, I’m here to share info and keep it light. Always do your own research, and don’t take this as financial advice. Catch you later!
• 
  PFE Today - Aug 07: Earnings Beat, Stock Slips 07.08.2026 1min

  Hey there! It’s Joey, your friendly longtime investor, here to break down the day. Today we’re talking about Pfizer, and it was a red day for them. The stock slipped about three-quarters of a percent. So, what went down? Pfizer’s earnings report was actually pretty solid. They beat expectations, which usually gets folks hyped, but today, that wasn’t enough. The stock got hit, even with their announcement of some hefty cost cuts—like $2.5 billion worth. That’s a big number, but it seems like investors weren’t feeling it. There was also some mixed news about their cancer drug from Seagen that didn’t really help boost confidence either. Now, why the mixed vibes? Well, even though they posted decent earnings, people are still worried about the bigger picture. Pfizer’s been dealing with some slow growth lately, and there's chatter about how they stack up against competitors like Merck. Plus, the fact that one of their higher-ups sold off some stock for over $80K raised a few eyebrows. It’s like, if they’re selling, should we be worried? That kind of stuff gets people thinking twice.Looking ahead, Pfizer did raise their guidance for the year. That’s a good sign, but it seems like it didn’t do much to lift spirits today. It’s like they’re trying to send a positive message while the stock just isn’t feeling it.So, yeah, that’s the scoop on Pfizer today. It’s a bit of a mixed bag, but that’s the market for you. Just remember, I’m here to keep you in the loop, not to give financial advice. Stay curious, keep learning, and catch you later!
• 
  PFE Today - Aug 06: Earnings Beat, Stock Still Slips 06.08.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor, breaking down what went down with Pfizer today. So, PFE had a bit of a red day, barely up at 0.62%. Now, here’s the scoop. Pfizer’s been all over the place lately. They reported earnings that actually beat expectations, which usually gives stocks a nice little boost, right? But instead of soaring, it kinda just hung around. People were hitting the sell button, probably because they saw some big red flags. One of their COVID drugs saw revenue drop a whopping 95%. Yeah, that one stung. Despite the earnings beat, there were some concerns about their future growth, especially with their obesity drugs not hitting the mark like they hoped. It’s like, they’re trying to pivot, but the market's not fully buying it, you know? They’re also making some big cuts – like $2.5 billion worth – which sounds good on paper but can freak investors out. It’s like, "What’s going on behind the scenes?" But hey, on the bright side, they’re still churning out cash, which is a good thing for shareholders. It’s kinda like a mixed bag right now. Some folks are optimistic, while others are a bit jittery. Oh, and just so you know, Pfizer’s trading at a premium even though it’s seen a 27% drop over the last five years. That’s a long haul, but it shows some resilience. So, in a nutshell, Pfizer had a rough day even with some decent earnings. There are definitely some things to keep an eye on as they navigate these choppy waters. That’s it for today! Just remember, this is all for fun and info, not financial advice. Catch you later!
• 
  PFE Today - Aug 05: Covid Pill Revenue Plummets 05.08.2026 1min

  Hey there! I'm Joey, your friendly neighborhood investor. Today, we’re talking about Pfizer, and it was a bit of a rough ride—down just a smidge, like barely 0.04%. Not a huge drop, but still, a red day.So, what went down? Pfizer's stock didn’t really move much, even though there was a big story about their Covid pill revenue crashing—like, down 95%. Ouch. But here’s the kicker: despite that massive drop, the stock was still kind of holding its ground. It’s like everyone was shrugging and saying, “Yeah, that stung, but we’ve got other stuff going on.”Now, why did it manage to stay afloat? Well, they just reported their Q2 earnings, and they actually beat expectations by a decent margin. But, and here’s the twist, they had a $4.3 billion writedown that stole the spotlight. So, people are looking at the earnings and thinking, “Okay, there’s some good news here,” but then they see that huge writedown and it’s kinda like a wet blanket on the party. It’s a mixed bag, for sure.And there’s more—Pfizer’s been working on a Lyme disease vaccine that’s showing about 70% efficacy. That’s some solid news, but with all this other noise, it’s hard to tell how much it’s influencing the stock. Plus, there are some concerns about their pipeline, which might be making investors a bit jittery.On the horizon, it’s worth knowing that the market's been kind of skeptical about Pfizer’s future revenue, especially with all the chatter about their pipeline. So, they’ve got some hurdles to clear.So, there you have it! Pfizer’s got some ups and downs, and while the stock didn’t crash today, it’s clear there’s a lot to unpack. Remember, this is just for info and fun—no financial advice here. Catch ya later!
• 
  PFE Today - Aug 04: Covid Pill Revenue Plunges 04.08.2026 1min

  Hey, what’s up? It’s Joey here, your friendly stock guy, and I’ve been investing for a minute. Today we’re talking about Pfizer, and it was a bit of a red day for them, down about half a percent. Not the end of the world, but yeah, it wasn’t great.So, what went down? Pfizer’s stock kinda got smoked today, mainly because their Covid pill revenue took a massive hit—like, a 95% drop. Ouch! That’s a big deal, right? But here’s the kicker: even with that bad news, Pfizer still managed to raise its revenue guidance for the year. They bumped it up by $500 million. Talk about mixed signals! Investors seemed to be scratching their heads a bit, trying to figure out how to feel about all this.Now, why did the stock react this way? Well, the earnings report showed some solid overall numbers, and despite that plummet in Covid pill sales, they’re still seeing growth elsewhere. So, while one part of the business is tanking, other areas are holding it up. It’s like having a leaky boat but still floating because you’ve got some good life jackets on board. People are still trying to wrap their heads around what this all means for Pfizer’s future.Looking ahead, Pfizer’s been a bit of a dud over the last five years, but they’ve still got that juicy 6.9% yield. That’s something to keep in mind if you’re into dividends. It’s a bit of a mixed bag, for sure. So, to wrap it all up, Pfizer had a rough day with that Covid pill revenue crash, but they’re also raising guidance, which is confusing. Just keep an eye on how they manage to balance these ups and downs. Remember, this is just for fun and info, not financial advice. Catch you later!
• 
  PFE Today - Aug 03: Lyme Vaccine Shows Promise 03.08.2026 1min

  Hey there! It's Joey, your friendly longtime investor, here to break down the day for Pfizer. So, PFE had a bit of a chill day, barely moving, just up a tiny bit—like 0.34%. What happened? Well, the stock didn’t really make any big moves today. It was kind of a slow bleed, you know? Nothing too dramatic on the charts. But here’s what’s interesting—Pfizer’s Lyme disease vaccine showed some solid numbers, hitting 70% efficacy. That’s a big deal in the vaccine world! Now, why did the stock act like it was on cruise control? A few things played into it. First, there’s excitement about that Lyme vaccine, which might get people thinking about future revenue streams. But, on the flip side, there’s a big earnings report coming up tomorrow. Earnings can really shake things up, so investors might be playing it safe, just waiting to see what happens next. Plus, there’s some chatter about COVID stuff still hanging around, which can always throw a wrench in the plans.And speaking of what’s on the horizon, just a heads up that Pfizer’s Q2 earnings report is dropping tomorrow. That’ll be the big moment for them, and it could change the game depending on what they say.So, yeah, that’s the scoop on Pfizer today. It’s a mix of cautious optimism with that Lyme vaccine news and the big earnings report looming. Just remember, I’m here for info and entertainment, not to give you financial advice. Catch you later!
• 
  PFE Today - Aug 02: Slight Gain Before Earnings 02.08.2026 1min

  Hey there! It’s Joey, your friendly investor buddy, breaking down the day for you. Today, we’re chatting about Pfizer — and guess what? It was a green day! The stock ticked up about 0.4%. Not a huge jump, but hey, it’s better than getting smoked.So, what went down? Pfizer’s stock kinda just floated up a bit. There was a lot of buzz around the company as folks are gearing up for their Q2 earnings report. They’ve got this weight loss drug in late-stage trials that’s got some potential, which is pretty exciting. Plus, some chatter around their drug Eliquis seems to be giving them a nice boost too. Now, why did it move like this? Well, a few articles pointed out that there’s some optimism around Pfizer’s overall performance and future growth. People are looking at their earnings potential and thinking, “Hey, this could be a solid play.” Plus, they’re trading at a pretty low multiple, which usually gets investors interested. But honestly, there’s still a lot of folks scratching their heads about why it isn’t getting more love. Like, it’s yielding 6.8%, but many are still ignoring it. It’s a bit of a mystery, really. Oh, and one thing that could be on the horizon is that Q2 earnings report coming up. That’s always a big deal for stocks like this. It’ll be interesting to see how they spin their numbers and if that weight loss drug really turns heads. So, to wrap it up, Pfizer had a chill day, inching up before the earnings drop. Keep an eye on those upcoming results, though! Just remember, this is all for fun and info, not financial advice. Catch you later!
• 
  PFE Today - Aug 01: Mixed Signals Ahead 01.08.2026 1min

  Hey there! It’s Joey, your go-to guy for stock chatter. I’ve been in this game for years, and today we’re looking at Pfizer, or PFE, and guess what? It was a bit of a slow day, barely up 0.4%. Not exactly fireworks, right? So, here’s the scoop. Pfizer’s stock kinda floated around today, not too much movement. It opened, did its thing, and closed right around $25.01. Volume was pretty steady, just like it usually is. Nothing wild on that front. Now, why did it move the way it did? Well, some folks were pretty pumped about their Lyme disease vaccine showing a solid 70% efficacy. That definitely got some chatter going. There’s also buzz about Eliquis, their blood thinner, showing strength in the market, which is always a good sign. But then, there was a little mix-up with some cancer drug results that didn’t quite hit the mark. So, it’s like a mixed bag—some good news, some not so great. That’s probably why the stock didn’t really go anywhere. Looking ahead, there’s talk about their pipeline being strong, and some analysts are giving it a solid forecast, like a potential 15% upside. That’s a nice little nugget for those keeping score. So, yeah, today was kinda chill for Pfizer. A few good vibes, a few bummers, and that’s how it goes sometimes in the stock world. Just remember, I’m here to keep you in the loop, but this isn’t financial advice—just some friendly stock talk. Catch you later!
• 
  PFE Today - Jul 31: Lyme Vaccine News 31.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. Today, I’m breaking down Pfizer, or PFE as we like to call it. It was a bit of a flat day, down just a smidge, like 0.3%. Not a huge deal, but still a red day.So, what went down? Well, the stock didn’t really budge much, hanging around that $24.83 mark. It’s like it was just chillin’ there, not making any big moves. Volume was steady, so no wild swings today. Now, let’s chat about why it played out this way. There’s some buzz around Pfizer’s Lyme disease vaccine, which is showing some promising results with 70% efficacy. That’s pretty solid! But even with that good news, it seems like investors are still a bit cautious, especially with earnings coming up soon. There’s chatter in the air about whether it’s the right time to buy or not, and people are weighing their options. Plus, there’s a lot of talk about Pfizer being mispriced. Some folks think the market hasn’t fully caught on to its potential, while others are still on the fence. It’s a mixed bag, really. As for what’s on the horizon? Well, earnings are right around the corner, and that could shake things up a bit. People are definitely going to be watching for any surprises or updates from the company. Alright, that’s the scoop for today! Just remember, this is all for fun and info, not financial advice. Stay savvy out there, and catch you later!
• 
  PFE Today - Jul 30: Earnings Ahead, Stock Slips 30.07.2026 1min

  Hey there! It’s Joey here, your friendly longtime investor, breaking down the day for you. Today, we’re talking about Pfizer, and it was a red day for them, down about 2.25%. Ouch!So, what went down? Well, PFE got smoked today, slipping in price and leaving some folks scratching their heads. The stock was pretty steady for a bit but then just couldn’t hold onto its gains. Now, why did this happen? There’s a lot of chatter about Pfizer's upcoming Q2 earnings report. People are wondering if the numbers will impress or disappoint. Some analysts think the stock's looking fairly valued, but there’s a sense of concern about weaker earnings coming up. Plus, there’s buzz about their new Lyme disease vaccine showing decent efficacy, but it doesn’t seem to have lit a fire under the stock today. And speaking of what's ahead, they’ve got a strong pipeline of products, but investors are a bit cautious. They’re keeping a close eye on how Pfizer navigates the next few quarters, especially with earnings looming. So, in short, Pfizer’s day wasn’t great, and folks are feeling a little jittery with earnings right around the corner. Just remember, this info is for fun and knowledge, not financial advice. Catch you later!
• 
  PFE Today - Jul 29: Weaker Earnings, Strong Pipeline 29.07.2026 1min

  Hey there! It’s Joey, your friendly stock buddy, and I’ve been in the investing game for years. Today, let’s talk about Pfizer, or PFE if you’re into the tickers. It was a pretty chill day for the stock—barely moved, just hanging out at the same price.So, what went down? The stock didn’t really budge, like it was stuck in neutral. Volume was steady but nothing crazy. It’s like the market was waiting for something to happen, but today, it was just a slow day for PFE.Now, why the stall? Well, there’s a lot of chatter about Pfizer’s pipeline. They’ve got some solid stuff coming down the line, which is good news, but the earnings reports are looking a bit weak. The analysts are saying the stock seems fairly valued, which means folks aren’t rushing to buy or sell. It’s like they’re just hanging back, waiting to see how things shake out. Plus, there’s buzz about their Lyme disease vaccine showing some impressive numbers—70% efficacy. That’s a big deal! But the mixed signals in earnings are keeping investors on their toes. Oh, and here’s a little nugget for you: there’s an earnings release coming up on August 4. Some folks are thinking the stock might move around 3% after that. So, keep an eye out if you’re following PFE closely.Alright, that’s the scoop for today! It’s all about staying informed and having a little fun with it. Just remember, I’m here to share info and keep it light, not to give financial advice. Catch you later!
• 
  PFE Today - Jul 28: Earnings Buzz and Dividend Talk 28.07.2026 1min

  Hey there! It’s Joey, your friendly longtime investor, here to break down the day. Today we’re chatting about Pfizer, and guess what? It was a green day, up about 2.9%. Not too shabby!So, what went down? Pfizer’s stock got a nice little boost, and it seems like folks are feeling a bit more optimistic. There’s a buzz around their upcoming earnings report, which is always a big deal. Plus, the chatter about their 7% dividend is getting some attention, especially with people looking closely at cash flow. Seems like investors are trying to figure out if that dividend is solid or if they need to worry.Now, why did this happen? Well, a couple of things are in play. First off, there’s been some positive noise about Pfizer's oncology growth with their drug Padcev and some promising pipeline expansions. That’s got people thinking, “Hey, maybe there’s more to this stock than we thought.” On top of that, Wall Street is weighing in with mixed feelings, but overall, it seems like the bulls are winning this round. The market’s got its eyes peeled on how Pfizer’s balancing their dividend with their cash flow, and that’s got folks debating.Oh, and here’s a quick thing to keep in mind: there’s some ongoing litigation around Pfizer's mRNA patent suits involving BioNTech’s technology. That could shake things up a bit in the future, so we’ll want to keep an eye on how that plays out.To wrap it up, Pfizer’s looking decent today with that nice little bump, fueled by earnings anticipation and dividend discussions. Just remember, this is all for fun and info, not financial advice. Catch you later!
• 
  PFE Today - Jul 27: FDA Review Sparks Interest 27.07.2026 1min

  Hey there! It’s Joey here, your friendly stock enthusiast, and I've been in the investing game for years. Today, we're talking about Pfizer, and it was a bit of a green day for them, up just a smidge by about 0.81%. So, what happened? Well, the stock saw some movement, but nothing wild. It was mostly stable, hanging around that $24.74 mark. There was some buzz in the air, though, thanks to the FDA giving a priority review for one of Pfizer's drugs aimed at prostate cancer. That got people chatting and maybe even a little excited.Now, why did Pfizer see this slight uptick? The big news is that their prostate cancer treatment is getting some serious attention from the FDA. Priority reviews are a big deal – they can speed up the approval process, and investors love that because it could mean potential revenue coming in sooner rather than later. Plus, there’s chatter about Pfizer's Lyme disease vaccine showing a solid 70% efficacy. That's promising, right? But honestly, a lot of the day’s movement seems to be tied to the prostate cancer news.On the horizon, keep your eyes peeled for more updates on the FDA’s decision. That could really shake things up for Pfizer if it goes their way. Alright, that's a wrap for today! Remember, I’m just here to share the scoop, not to give any advice on buying or selling. Have a good one!
• 
  PFE Today - Jul 26: Lung Cancer Trial Disappointment 26.07.2026 1min

  Hey, what’s up? It’s Joey here, your friendly investor buddy. Just breaking down the day for you. Today, we're talking about Pfizer, and it was a red day—down about 1.9%. Ouch!So here’s the scoop. Pfizer's stock took a hit today, and honestly, it got smoked. The main reason? They had some disappointing news from a lung cancer trial. Investors were expecting big things, but when the results came in, it was more of a letdown. You know how it goes—people hit the sell button fast when things don’t look good. Now, while the lung cancer news was a bummer, there was also some chatter about Ibrance, which is one of their cancer drugs. They had a win there, but honestly, it got overshadowed by the lung cancer trial mess. So, it’s like they got one good thing and one bad thing, but the bad thing really stole the spotlight.Then there's the whole dividend situation. Some articles mentioned that Pfizer's dividend yield looks pretty enticing, almost too good to be true. But management seems chill about it, saying they’re not worried. That’s a good sign for folks who love dividends, but it’s like, can they keep it up? Also, don’t forget they’re still trying to push their AI healthcare stuff. Some analysts are saying Pfizer is one of the top names to watch in that space. So, while today was rough, there might be some interesting developments coming.Anyway, that’s the lowdown for today. Just keep in mind this is all for info and entertainment, not financial advice. Catch you later!
• 
  PFE Today - Jul 25: Lung Cancer Trial Disappointment 25.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, and I’m here to break down what went down with Pfizer today. So, PFE had a rough day, dropping about 1.9%. Yeah, that one stung.Here’s the scoop: Pfizer’s stock got smoked because of some disappointing news from a lung cancer trial. Investors were really hoping for a win there, but it didn’t pan out, and that sent people racing for the exits. The market didn’t like it at all. On top of that, there was some buzz around their dividend yield looking pretty solid, but honestly, that wasn’t enough to stop the bleeding today.Now, why did the lung cancer trial hit so hard? Well, it seems like the results didn’t meet the expectations that folks had. You know how it goes; when you’re banking on good news and it falls flat, people get jittery. They start hitting the sell button fast, and that’s exactly what happened here. It overshadowed any positive vibes from other parts of the business, like their recent win with Ibrance, which is supposed to be a game-changer for breast cancer treatment. But alas, that good news couldn’t overshadow the bad.Also, I saw some chatter about Pfizer being on a shortlist of cheap income stocks. That’s cool and all, but when you’ve got a cloud of disappointment hanging over you, it’s tough to get the hype train rolling. And hey, they did have some good news about a Lyme disease vaccine showing 70% efficacy. But again, it seems like nobody’s paying much attention to that when the lung cancer news is fresh in their minds.One thing worth knowing is that folks are still keeping an eye on Pfizer's dividend yield. It’s looking almost too good to be true, and management doesn’t seem worried about it. So, while today was rough, there are still some bright spots in the background.Alright, that’s the lowdown on Pfizer today. Just remember, I’m here to share info and keep it fun, not to give any financial advice. Catch you later!